On December 3, 2020, Everlywell, a leading digital health company, announced an oversubscribed Series D financing of $175 million. New investors participating in the round include funds and accounts managed by BlackRock, The Chernin Group (TCG), Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, and Portfolia, as well as existing investors Goodwater Capital, Highland Capital Partners, and Next Coast Ventures. This investment brings the total capital raised by the company to over $250 million, which includes a Series C round led by Highland Capital Partners earlier this year. Wilson Sonsini advised Everlywell in connection with the financing.

"The pandemic has shed light on the challenges of lab testing for Americans, from unknown costs to confusion and inconvenience. We've been empowering people with a new way to get tested for five years and will continue to lead the way in a rapidly expanding space," said Julia Cheek, Everlywell founder and CEO. "We believe lab testing will be rapid, simple, and coupled with virtual care in the near future. This partnership with additional world-class investors enables us to build a transformative, multi-generational digital health company that puts people first—where they belong."

The company plans to use the funds to expand its virtual care offerings, scale its testing and infrastructure, drive clinical research and disease management through testing, and grow its national leadership position in the at-home testing market.

The Wilson Sonsini team that advised Everlywell includes the following attorneys:

Corporate:
Megan Baier
Brandon Middleton-Pratt
Virginia Harris

Technology Transactions:
Jennifer McGrew

Privacy:
Matt Staples

Please see Everlywell’s press release for more information.